Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunocore Holdings plc - American Depositary Shares (NQ: IMCR )

28.66 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunocore Holdings plc - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday
Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in... 
Via Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
Via Benzinga
Immunocore Shares Fall After Early Solid Cancer Trial Data Of TCR Therapy
Via Benzinga
Immunocore Eye Cancer Cell Therapy Scores European Approval
The European Commission (EC)  
Via Benzinga
FDA Approves First T Cell Receptor Therapy From Immunocore For Eye Cancer
The  
Via Benzinga
Dow Climbs More Than 400 Points, S&P 500 Rises 1.5%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 400 points on Friday. 
Via Benzinga
Stocks Extend Gains, Weekly Wins In Sight
Stocks are extending this morning's gains, with the Dow Jones Industrial Average last seen up 317 points. 
Via Talk Markets
Analyzing Immunocore Hldgs's Short Interest
Immunocore Hldgs's (NASDAQ:IMCR) short percent of float has fallen 15.71% since its last report. The company recently reported that it has 902 thousand shares sold short, which is... 
Via Benzinga
Why Zscaler Is Trading Higher By Around 19%, Here Are 44 Stocks Moving In Friday's Mid-Day Session
Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares jumped 70% to $2.1750 after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in cash. 
Via Benzinga
Nasdaq Jumps Over 200 Points, Crude Oil Rises Sharply
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday. 
Via Benzinga
Enphase Energy, Immunocore And Some Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
US Stocks Open Higher, Dow Surges 300 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. 
Via Benzinga
Bed Bath & Beyond, Eiger BioPharmaceuticals And Some Other Big Stocks Moving Lower On Tuesday
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
Not all shares are slowing down alongside the industry group. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
  
Via Benzinga
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to... 
Via Benzinga
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022
  
Via Benzinga
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Immunocore Commences Initial-Stage HIV Study
Immunocore Holdings (NASDAQ: IMCR) has dosed the first patient in the first-in-human Phase 1 clinical trial of IMC-M113V for the treatment of patients with human immunodeficiency virus (HIV)... 
Via Benzinga
4 Biotech Stocks With Bright Prospects To Buy Amid Recovery
New drug approvals, acquisitions, and other pipeline developments are back in the spotlight in the biotech industry, following the focus on the development of vaccines and antibody treatments for... 
Via Talk Markets
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
Via Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2022
Upgrades According to Consumer Edge Research, the prior rating for The Hain Celestial Group Inc (NASDAQ:HAIN) was changed from Equal-Weight to Overweight. For the second... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. 
Via Benzinga
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.